Lancet Diab & Endo：大庆糖尿病预防研究23年随访结果公布

2014-04-04 佚名中国医学论坛报

4月3日，北京中日友好医院李光伟教授等在《柳叶刀·糖尿病与内分泌学》(The Lancet Diabetes & Endocrinology)杂志发表了“大庆糖尿病预防研究”23年随访结果：中国糖耐量受损人群进行生活方式干预6年，随访23年显示心血管病死亡和全因死亡显著降低。这是全球首项证明生活方式干预可降低糖尿病高危人群心血管病死亡和全因死亡的高质量随机对照试验。 1986年，

4月3日，北京中日友好医院李光伟教授等在《柳叶刀·糖尿病与内分泌学》(The Lancet Diabetes & Endocrinology)杂志发表了“大庆糖尿病预防研究”23年随访结果：中国糖耐量受损人群进行生活方式干预6年，随访23年显示心血管病死亡和全因死亡显著降低。这是全球首项证明生活方式干预可降低糖尿病高危人群心血管病死亡和全因死亡的高质量随机对照试验。

1986年，李教授等将糖耐量受损患者随机分为生活方式干预组(n=438)和对照组(n=138)，干预组给予生活方式干预6年。随访23年显示，心血管病导致的累计死亡率在生活方式干预组为11.9%，在对照组为19.6%;全因死亡率在生活方式干预组为28.1%，在对照组为38.4%。

英国剑桥大学韦勒姆教授在同期述评中将上述结果描述为“一个真正的突破”。

详细阅读：Lancet Diab & Endo：对糖耐量受损者（IGT）进行生活方式干预显示出长期获益

原始出处：

Guangwei Li, Ping Zhang, Jinping Wang, Yali An, Qiuhong Gong, Edward W Gregg, Wenying Yang, Bo Zhang, Ying Shuai, Jing Hong, Michael M Engelgau, Hui Li, Gojka Roglic, Yinghua Hu, Peter H Bennett.Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study . In Press, Corrected Proof, Available online 3 April 2014

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (17)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问，是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创，造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接？, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的，所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
2014-09-12 朱睿睿

#糖尿病预防#

62 0
[GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问，是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创，造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接？, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的，所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
2014-07-02 shanyongle

#结果公布#

61 0
[GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问，是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创，造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接？, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的，所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
2014-11-30 howi

#Lancet#

54 0
[GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问，是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创，造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接？, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的，所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
2014-07-23 维他命

#随访结果#

59 0
[GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问，是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创，造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接？, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的，所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
2014-04-14 ybf

李教授一直兢兢业业、一丝不苟的做学问，是晚辈们学习的楷模

152 0
[GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问，是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创，造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接？, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的，所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
2014-04-13 zhangyusheng

中国原创，造福世界

131 0
[GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问，是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创，造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接？, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的，所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
2014-04-09 liguojuan@2011

鼓舞人心！

140 0
[GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问，是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创，造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接？, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的，所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
2014-04-08 207.106.176.170

能不能给个链接？

170 0
[GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问，是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创，造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接？, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的，所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
2014-04-07 112.53.64.218

挺有意思的内容

168 0
[GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问，是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创，造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接？, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的，所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
2014-04-07 116.231.255.56

这个研究在东北大庆这个地方进行的，所以命名为大庆研究

122 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

内分泌科

Lancet Diab & Endo：大庆糖尿病预防研究23年随访结果公布

相关资讯

科室

工具

服务